|Articles|June 15, 2016
- BioPharm International-06-15-2016
- Volume 2016 ebook
- Issue 1
Outsourcing Industry Marked by Considerable Investments in 2016
Biopharmaceutical contractors continue to invest in development, facility upgrades, technological advancement, and mergers and acquisitions.
Advertisement
The biopharmaceutical outsourcing industry has been marked by investment in technology and facility upgrades, mergers, acquisitions, and development partnerships in 2016. This article details are some of the latest developments in the biopharmaceutical outsourcing market.
Download the
.
Articles in this issue
over 9 years ago
Contract Service Providers Gear Up to Develop Emerging Therapiesover 9 years ago
Biopharma Service Providers Address a Full Plate of Challengesover 9 years ago
Dealing with Pharmaceutical Supply-Chain Complexitiesover 9 years ago
Keeping it Simple: Collaborating for Success in Drug Deliveryover 9 years ago
Biomanufacturers Demand Higher Quality Standards in 2016over 9 years ago
Preventing Phase III FailuresNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Regulatory Challenges for Global Manufacturing of Vaccines
2
EU Biopharma Strategy: Scaling Up to Tackle Funding Gaps and Drive Innovation
3
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
4
Advances in Continuous Manufacturing, Drug Delivery Lead CPHI Pharma Awards 2025
5
